Status of Clinical Application of Yufeng Ningxin Preparations and the Meta-Analysis of Its Efficacy and Safety in the Treatment of Cardiovascular and Cerebrovascular Diseases

Lishuang Zhang1  Yaxia Ma1  Ying Wang2  Feng Jiang3

1Internal Medicine-Cardiovascular Department, The Fourth Affiliated Hospital of Tianjin University of Traditional Chinese Medicine and Tianjin Binhai New Area Hospital of Traditional Chinese Medicine, Tianjin, China
2Jinrun Pharmaceutical Co., Ltd Tianjin, China
3Institute of International Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China

CMNP 2022;2:e96–e106.

Abstract

Objective  The objective of this study was to analyze the status of the clinical application of Yufeng Ningxin (YFNX) preparations and systematically evaluate their efficacy and safety in the treatment of cardiovascular and cerebrovascular diseases.

Methods  Through searching databases of China National Knowledge Infrastructure, Wanfang, SinoMed, VIP, PubMed, Embase, and the Cochrane Library, the literature of clinical research on YFNX preparations in treating malignant tumors of cardiovascular and cerebrovascular diseases from the establishment of the databases to February 2021 was collected. The clinical randomized controlled trials and case–control studies of cardiovascular and cerebrovascular diseases treated with these preparations were analyzed. Two reviewers independently screened literature, extracted data, and assessed the risk of bias in the included studies, and meta-analysis was performed by using ReMan 5.3 software to analyze the efficacy and safety of YFNX preparations in the treatment of cardiovascular and cerebrovascular diseases.

Results  A total of 29 clinical studies were finally included. The dosage forms were dropping pills, tablets, capsules, and granules. The preparations were used for the treatment of coronary heart disease, hypertension, neuropathic headache, etc. This study systematically evaluated the efficacy and safety of YFNX preparations in the treatment of coronary heart disease, hypertension, and nervous headache. A total of 1,162 cases were included in 13 studies, 582 cases of the YFNX preparation group and 580 cases of the Western medicine group. The results of meta-analysis showed that the clinical efficacy of YFNX preparations combined with the Western medicine group in the treatment of coronary heart disease and hypertension, improving electrocardiogram and reducing the frequency and duration of angina attacks, was...
Introduction

Yufeng Ningxin (YFNX) preparations are pure Chinese medicine preparations, and the main ingredient is Gegen (Pueraria Lobatae Radix). Gegen (Pueraria Lobatae Radix) was first recorded in Shennong’s Classic of Materia Medica(Shen Nong Ben Cao Jing). It is sweet, pungent in flavor, and cool in nature, with the functions of relieving the exterior, reducing fever, producing body fluid, expelling skin rash, raising yang, and stopping diarrhea. It can be used for headaches due to exogenous fever, stiff neck and back pain, thirst, consumptive thirst, measles, heat dysentery, diarrhea, etc., as mentioned in Shennong’s Classic of Materia Medica(Shen Nong Ben Cao Jing). “It dominates consumptive thirst, high fever of the body, vomiting, various Bi syndromes, lifting yin fluid and eliminating toxicity.” Gegen (Pueraria Lobatae Radix) contains chemical components of isoflavones, saponins, alkaloids, coumarins, and polysaccharides, among which isoflavones are the most abundant, mainly including daidzin, daidzein, puerarin, etc. The ingredient of the highest content is puerarin. Modern pharmacological studies have shown that puerarin has the functions of protecting blood vessels, resisting oxidative stress, fighting against infection, lowering blood sugar, regulating blood lipids, improving insulin sensitivity index, etc., and has few adverse reactions. It has been clinically applied to the diseases such as cardiovascular and cerebrovascular diseases, cancer, Parkinson’s disease, Alzheimer’s disease, diabetes, and diabetic complications. Cardiovascular and cerebrovascular diseases are characterized by high morbidity, disability rate, mortality rate, and recurrence rate. With the aging of the population in China, the incidence of cardiovascular and cerebrovascular diseases shows a significant upward trend. It is reported that there are 330 million cardiovascular patients in China, including 13 million strokes, 11 million coronary heart disease, 8.9 million heart failure, and 245 million hypertension. Cardiovascular and cerebrovascular diseases have been a major public health problem and a prominent social problem. Therefore, it is imperative to give prevention and treatment. YFNX preparations mainly contain puerarin, which has the functions of relieving spasm and pain, enhancing cerebral and coronary blood flow, and has great advantages and potential in the prevention and treatment of cardiovascular and cerebrovascular diseases. However, it lacks a systematical review of the clinical application as well as the evaluations of the efficacy and safety in the prevention and treatment of cardiovascular and cerebrovascular diseases. This study comprehensively retrieved relevant clinical research at home and abroad to systematically analyze the clinical application status of YFNX preparations and evaluate the clinical efficacy and safety to provide a reference for clinical practice and decision-making.

Current Status of Clinical Application of Yufeng Ningxin Preparation

Materials and Methods

Data Sources
China National Knowledge Infrastructure (CNKI), Wanfang (WF), SinoMed, VIP, PubMed, Embase, and the Cochrane Library databases were searched to collect clinical studies related to YFNX preparations. The retrieval time limit was from the establishment of the databases to February 2021. The Chinese searching term was the English searching terms were YFNX and yu feng ning xin.

Inclusion and Exclusion Criteria of Literature (Self-Made)

The types of literature included in this study were clinical studies, involving YFNX dropping pills as a dosage form, and related preparations, and there were no restrictions on the types of diseases, course of treatment, and evaluation indicators. Theoretical discussions, clinical experience, case reports, animal experiments, and duplicate publications on YFNX preparations were excluded.

Data Extraction and Statistics

Two researchers independently searched and screened the literature and excluded literature that did not meet the inclusion criteria. If there was any disagreement, it was resolved through discussion or consultation with a third researcher. For the included literature, the entry was made, the data were extracted, and the double-entry check was performed according to the design form. This study extracted the literature information from four aspects: (1) the publication year of the literature; (2) the specific intervention measures and syndrome differentiation in each clinical study; (3) the dosage form of YFNX preparations; and (4) name of specific clinical disease treated by YFNX preparations.

Results

Literature Publication

By February 2021, a total of 396 related articles were retrieved. NoteExpress document management software was used to check duplicates and excluded 203 duplicate articles. By reading the titles and abstracts, 156 articles which obviously did not meet the inclusion criteria were
excluded. After reading the full texts, 8 articles that did not meet the inclusion criteria were excluded and 29 articles were finally included. The included 29 clinical studies were counted according to the year of publication. The results showed that the earliest clinical study was published in 1988, and the number of studies was increasing year by year. See Fig. 1.

Analysis of Dosage Forms, Clinical Syndromes, Research Types, and Intervention Measures Used in Clinical Research of Yufeng Ningxin Preparations

Among the 29 clinical studies included, YFNX preparations were included in 17 studies in the form of dropping pills, 9 studies in the form of tablets, 2 studies in the form of granules, and 1 study in the form of capsules. The three studies involved TCM syndromes, namely yin deficiency and yang hyperactivity syndrome, heart blood stagnation syndrome, and qi stagnation and blood stasis syndrome. The types of studies involved 15 case-control studies, 11 clinical randomized controlled studies, and 3 before-after self-control studies. The intervention measures involved seven kinds: YFNX preparations versus Chinese medicine, YFNX preparations versus Western medicine group, YFNX preparations + Western medicine group versus Western medicine group, YFNX preparations + Chinese medicine versus Chinese medicine and so on. See Table 1.

Analysis of Yufeng Ningxin Preparations in the Clinical Treatment of Diseases

In the included clinical studies, YFNX preparations were used for the treatment of nine kinds of clinical diseases, namely coronary heart disease, neuropathic headache, hypertension, vertebrobasilar insufficiency (vertigo), transient cerebrovascular attack, chronic heart rhythm disorders, cerebral vasospasm, sudden deafness, myocardial ischemia.

Meta-Analysis of the Efficacy and Safety of Yufeng Ningxin Preparations in the Treatment of Cardiovascular and Cerebrovascular Diseases

Materials and Methods

Inclusion Criteria (Self-Made)

(1) The types of studies in the included literature were clinical randomized controlled trials and case-control studies; (2) the subjects of the studies were patients who were clinically diagnosed with cardiovascular and cerebrovascular diseases (coronary heart disease, hypertension, and neuropathic headache), and the age and course of the disease were not limited; (3) the intervention measures were YFNX preparations versus Western medicine group and YFNX preparations + Western medicine group versus Western medicine group (the chemotherapy regimens of the experimental group and the control group in the same study must be consistent); and (4) the main observation indicators involved clinical efficiency, pain scale, and so on.

Exclusion Criteria (Self-Made)

Exclusion criteria were (1) before-after self-control study, cross-sectional study; (2) experiments involving interventions
Table 1 Summary of the clinical research on the intervention measures of YFNX preparations

<table>
<thead>
<tr>
<th>Included research literature</th>
<th>T</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ye and He 2020</td>
<td>YFNX dropping pills</td>
<td>YFNX tablets</td>
</tr>
<tr>
<td>Yan et al 2020</td>
<td>YFNX dropping pills + C</td>
<td>Western medicine routine 1</td>
</tr>
<tr>
<td>Cheng 2019</td>
<td>YFNX dropping pills + C</td>
<td>general antihypertensive drugs</td>
</tr>
<tr>
<td>Yang 2019</td>
<td>YFNX dropping pills + C</td>
<td>Western medicine routine 2</td>
</tr>
<tr>
<td>Cheng and Jia 2019</td>
<td>YFNX tablets + C</td>
<td>Nifedipine sustained release tablets</td>
</tr>
<tr>
<td>Sun 2019</td>
<td>YFNX dropping pills</td>
<td>Flunarizine hydrochloride capsules</td>
</tr>
<tr>
<td>Chen and Wang 2018</td>
<td>YFNX dropping pills + C</td>
<td>Western medicine routine 3</td>
</tr>
<tr>
<td>Zheng and Xiao 2017</td>
<td>YFNX dropping pills + C</td>
<td>Western medicine routine 4</td>
</tr>
<tr>
<td>Yan 2017</td>
<td>YFNX dropping pills + C</td>
<td>Flunarizine hydrochloride capsules</td>
</tr>
<tr>
<td>An 2017</td>
<td>YFNX dropping pills</td>
<td>Flunarizine hydrochloride capsules</td>
</tr>
<tr>
<td>Dou 2016</td>
<td>YFNX dropping pills</td>
<td>Flunarizine hydrochloride capsules</td>
</tr>
<tr>
<td>Guo et al 2014</td>
<td>YFNX dropping pills + moxibustion</td>
<td>YFNX dropping pills</td>
</tr>
<tr>
<td>He 2014</td>
<td>YFNX tablets + C</td>
<td>conventional antihypertensive drugs</td>
</tr>
<tr>
<td>Liang et al 2014</td>
<td>YFNX dropping pills + C</td>
<td>Western medicine routine 5</td>
</tr>
<tr>
<td>Fu 2014</td>
<td>YFNX dropping pills</td>
<td>Flunarizine hydrochloride capsules</td>
</tr>
<tr>
<td>Xing et al 2013</td>
<td>YFNX tablets + Moriczine tablets</td>
<td>Wenxin granules</td>
</tr>
<tr>
<td>Liang et al 2011</td>
<td>YFNX dropping pills</td>
<td>——</td>
</tr>
<tr>
<td>Shi 2011</td>
<td>YFNX tablets + Nimodipine</td>
<td>——</td>
</tr>
<tr>
<td>Yang et al 2010</td>
<td>YFNX tablets + Ginkgo Damo injection</td>
<td>Anisodamine + Flunarizine hydrochloride</td>
</tr>
<tr>
<td>Feng 2007</td>
<td>Massage</td>
<td>YFNX dropping pills</td>
</tr>
<tr>
<td>Zhang et al 2006</td>
<td>YFNX dropping pills</td>
<td>Zhenianoing capsules</td>
</tr>
<tr>
<td>Zhu et al 2004</td>
<td>YFNX dropping pills + YFNX tablet simulators</td>
<td>YFNX tablets + YFNX dropping pill simulators</td>
</tr>
<tr>
<td>Sun 2003</td>
<td>YFNX tablets</td>
<td>Di'a Xinxue Kang</td>
</tr>
<tr>
<td>Zheng 2003</td>
<td>Tongxinluo capsules</td>
<td>YFNX tablets</td>
</tr>
<tr>
<td>Liu et al 2003</td>
<td>YFNX tablets</td>
<td>Danshen tablets</td>
</tr>
<tr>
<td>Gu 2001</td>
<td>YFNX granules + Danshen injection</td>
<td>Danshen injection</td>
</tr>
<tr>
<td>Wang et al 1999</td>
<td>YFNX granules</td>
<td>YFNX tablets</td>
</tr>
<tr>
<td>Ling and Li 1988</td>
<td>YFNX tablets + Amiodarone</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>Peng 2015</td>
<td>YFNX capsules + Compound Danshen injection</td>
<td>——</td>
</tr>
</tbody>
</table>

Abbreviation: “——”, the research does not involve this item; C, medication in the control group; T, medication in the treatment group; YFNX, Yufeng Ningxin.

Notes: Western medicine routine 1: mainly includes antiplatelet aggregation, nitrates, betablockers, etc., and nitroglycerin tablets are taken when angina pectoris occurs; Western medicine routine 2: low molecular weight heparin, statins, aspirin, isosorbide mononitrate; Western medicine routine 3: anticoagulation, nitrates, calcium channel blockers, lipid regulation, antiplatelet, etc.; Western medicine routine 4: antiplatelet aggregation, stabilizing plaque, nourishing myocardium, etc.; Western medicine routine 5: aspirin, clopidogrel, low molecular weight heparin, statins, isosorbide mononitrate, etc., sublingual intake of nitroglycerin during angina attack.

by other Chinese herbs; (3) repeated publications; and (4) the original data that cannot be extracted and cannot be obtained after contacting the author.

Retrieval Strategy
The data source was the same as 2.1.1. In addition, the references and relevant systematic reviews of the included studies were retrospectively reviewed to supplement relevant literature. The Chinese searching term was Yu Feng Ning Xin, and the English searching terms were Yufeng Ningxin, yu feng ning xin.

Literature Screening and Data Extraction
Two researchers independently screened the literature and extracted data and cross-checked them. Disagreements were discussed and resolved, and a third party was consulted to assist in judgment. The data were extracted using a preestablished data extraction form, and the extracted contents included (1) basic information of the included studies, including the first author, title, publication year, etc.; (2) the basic information of the patients, including the number of cases, age, etc.; (3) intervention measures, including the
use of drugs, doses, courses of treatment, etc.; (4) observation indicators and result measurement data; (5) follow-up time; and (6) methodological-related information.

Risk of Bias Assessment of the Included Studies

Clinical randomized controlled studies: According to the modified Jadad scale, the methodological quality of the included studies was evaluated from four aspects: random sequence generation, allocation concealment, blinding, withdrawal, or loss of follow-up (7 points as full score, 4–7 points as high quality, 1–3 points as low quality). Case-control study: The Newcastle–Ottawa scale was used to evaluate the quality of the included literature. The scale consisted of three dimensions and eight items, with a total score of 0 to 9. The evaluation included (1) selection of the study population: appropriateness of the cases determination, representativeness of cases, selection of control drugs and determination of control drugs, a total of four items, 4 points; (2) comparability between groups: the comparability of the case drugs and the control drugs, a total of one item, 2 points; and (3) outcome measurement or exposure factor measurement: determination of exposure factors, determination of the case and control exposure factors using the same method, nonresponse rate, a total of three items, 3 points. Total score < 4 indicated low-quality research literature, 4 to 6 indicated medium-quality research literature, and ≥ 6 indicated high-quality research literature. In the quality evaluation, two researchers independently evaluated, and if there was a dispute, a third researcher was invited to arbitrate.

Statistical Methods
Revman 5.3 software was used for meta-analysis, the relative risk (RR) was used as the effect index for enumeration data, and the mean difference (MD) was used as the effect index for measurement data. Point estimate and 95% confidence interval (CI) were given to each effect size. The heterogeneity among included studies was analyzed by $\chi^2$ test, and the size of heterogeneity was quantitatively judged with $I^2$. If the heterogeneity among the results of the studies was not obvious ($I^2 \leq 50\%$), a fixed-effect model was used for meta-analysis. If there was obvious heterogeneity ($I^2 > 50\%$) among the studies, after excluding the obvious clinical heterogeneity, a random effect model was used for meta-analysis. The obvious clinical heterogeneity was progressed by subgroup analysis or sensitivity analysis, etc., or descriptive analysis was performed.

Results

Literature Search Results
According to the above searching strategy, a total of 396 articles were retrieved, including 95 articles from SinoMed database, 97 articles from CNKI database, 121 articles from WF database, and 83 articles from VIP database. NoteExpress was used to automatically check duplicates and obtain 193 articles. The title and abstract were read, 156 articles obviously inconsistent with the study were excluded, and 37 articles from the preliminary screening were obtained. After reading the full texts of the articles, 24 articles including other Chinese medicines or uncontrolled studies in the intervention measures were excluded, and 13 clinical studies were finally included.

Analysis of the Basic Characteristics and Quality

Evaluation of the Included Research Literature
A total of 13 research articles were included, including 6 clinical randomized controlled trials articles $^{5–7,10,11}$ and 7 case–control articles $^{8,9,12–14,16,18}$ One study included YFNX tablets$^{5}$ and the rest included YFNX dropping pills as dosage forms. Included studies were first published in 2014 and latest in 2020. A total of 1,162 patients with cardiovascular and cerebrovascular diseases were included in 13 research papers, including 582 cases of the YFNX preparation group and 580 cases of the Western medicine group. The Western medicine group involved conventional Western medicine intervention for coronary heart disease and angina pectoris, Western medicine of antihypertensive drugs, and flunarizine hydrochloride capsules. Diseases involved angina pectoris, hypertension, and neuropathic headaches. Observation indicators were clinical efficacy, the number of angina pectoris attacks, the duration of angina pectoris, the level of nitric oxide, the level of C-reaction protein, the number of headache attacks, the duration of headache, adverse reactions, etc. See Table 2.

Clinical Efficacy Analysis of Coronary Heart Disease, Hypertension, and Neuropathic Headache
The clinical efficacy included markedly effective, effective, and ineffective as the clinical judgment criteria. Five studies recorded the clinical efficacy of YFNX preparations + Western medicine group versus Western medicine group in the treatment of coronary heart disease $^{5,7,8,10,11}$ and the dosage forms were YFNX tablets and YFNX dropping pills, respectively. Two studies observed the clinical efficacy of YFNX preparations + Western medicine group versus Western medicine group in the treatment of hypertension. $^{6,16}$ The dosage forms were YFNX tablets and YFNX dropping pills, respectively. $^{5,16}$ Five studies observed the clinical efficacy of YFNX dropping pills + flunarizine hydrochloride capsules/YFNX dropping pills versus flunarizine hydrochloride capsules in the treatment of neuropathic headache. $^{9,12–14,18}$ The dosage forms were all in the form of YFNX dropping pills. The meta-analysis results of the fixed effect model showed that compared with the pure Western medicine group, the YFNX preparations + Western medicine group/YFNX preparation group could significantly improve the clinical efficacy of coronary heart disease, hypertension, and neuropathic headache, and the difference was statistically significant (RR = 1.25, 95%CI [1.16, 1.35], $p < 0.00001$; RR = 1.21, 95%CI [1.08, 1.36], $p = 0.0008$; RR = 1.29, 95% CI [1.17, 1.41], $p = 0.0008$). See Figs. 2–4.

Electrocardiogram Analysis of Coronary Heart Disease
Two studies reported the effect of YFNX preparations + Western medicine group versus Western medicine group
<table>
<thead>
<tr>
<th>Included research literature</th>
<th>Types of study</th>
<th>Curing disease</th>
<th>Number of cases (T/C)</th>
<th>Age</th>
<th>Interventions T C</th>
<th>Course of treatment</th>
<th>Outcome indicator</th>
<th>Jadad score</th>
<th>NOS score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yan et al 2020</td>
<td>Clinical randomized control</td>
<td>Angina pectoris</td>
<td>42/41</td>
<td>40–75</td>
<td>YFNX dropping pills + C</td>
<td>Western medicine routine 1</td>
<td>April</td>
<td>①②③④</td>
<td>4 points</td>
</tr>
<tr>
<td>Cheng and Jia 2019</td>
<td>Case–control study</td>
<td>Angina pectoris</td>
<td>46/46</td>
<td>40–68</td>
<td>YFNX Tablets + C</td>
<td>Nifedipine sustained release tablets</td>
<td>—</td>
<td>①②③④⑤⑥</td>
<td>5 points</td>
</tr>
<tr>
<td>Sun 2019</td>
<td>Case–control study</td>
<td>Neuropathic headache</td>
<td>61/61</td>
<td>39.2 ± 2.3</td>
<td>YFNX dropping pills</td>
<td>Flunarizine hydrochloride capsules</td>
<td>—</td>
<td>①②③④⑤⑥</td>
<td>3 points</td>
</tr>
<tr>
<td>Yang 2019</td>
<td>Clinical randomized control</td>
<td>Angina pectoris</td>
<td>45/45</td>
<td>67.0 ± 10.1</td>
<td>YFNX dropping pills + C</td>
<td>Western medicine routine 2</td>
<td>—</td>
<td>①</td>
<td>2 minutes</td>
</tr>
<tr>
<td>Cheng 2019</td>
<td>Clinical randomized control</td>
<td>Hypertension headache</td>
<td>40/40</td>
<td>53.92 ± 2.75</td>
<td>YFNX dropping pills + C</td>
<td>General antihypertensive drugs</td>
<td>—</td>
<td>①</td>
<td>3 points</td>
</tr>
<tr>
<td>Chen and Wang 2018</td>
<td>Clinical randomized control</td>
<td>Coronary heart disease</td>
<td>46/46</td>
<td>60.8 ± 5.5</td>
<td>YFNX dropping pills + C</td>
<td>Western medicine routine 3</td>
<td>4 wk</td>
<td>①②③④⑤⑥</td>
<td>3 points</td>
</tr>
<tr>
<td>Zheng and Xiao 2017</td>
<td>Clinical randomized control</td>
<td>Coronary heart disease</td>
<td>80/80</td>
<td>75.4 ± 1.38</td>
<td>YFNX dropping pills + C</td>
<td>Western medicine routine 4</td>
<td>10 d</td>
<td>①</td>
<td>3 points</td>
</tr>
<tr>
<td>Yan 2017</td>
<td>Case–control study</td>
<td>Migraine</td>
<td>29/29</td>
<td>45.1 ± 1.2</td>
<td>YFNX dropping pills + C</td>
<td>Flunarizine hydrochloride capsules</td>
<td>9 wk</td>
<td>①②③④⑥</td>
<td>3 points</td>
</tr>
<tr>
<td>An 2017</td>
<td>Case–control study</td>
<td>Neuropathic headache</td>
<td>39/38</td>
<td>37.8 ± 5.6</td>
<td>YFNX dropping pills</td>
<td>Flunarizine hydrochloride capsules</td>
<td>—</td>
<td>①</td>
<td>3 points</td>
</tr>
<tr>
<td>Dou 2016</td>
<td>Case–control study</td>
<td>Neuropathic headache</td>
<td>30/30</td>
<td>38.27 ± 4.57</td>
<td>YFNX dropping pills</td>
<td>Flunarizine hydrochloride capsules</td>
<td>—</td>
<td>①</td>
<td>3 points</td>
</tr>
<tr>
<td>Liang et al 2014</td>
<td>Clinical randomized control</td>
<td>Coronary heart disease</td>
<td>64/64</td>
<td>68.5 ± 9.1</td>
<td>YFNX dropping pills + C</td>
<td>Western medicine routine 5</td>
<td>15 d</td>
<td>①②③④⑤⑥</td>
<td>3 points</td>
</tr>
<tr>
<td>He 2014</td>
<td>Case–control study</td>
<td>Hypertension</td>
<td>42/42</td>
<td>35–60</td>
<td>YFNX Tablets + C</td>
<td>Conventional antihypertensive drugs</td>
<td>4 wk</td>
<td>①</td>
<td>3 points</td>
</tr>
<tr>
<td>Fu 2014</td>
<td>Case–control study</td>
<td>Neuropathic headache</td>
<td>18/18</td>
<td>32.41 ± 1.03</td>
<td>YFNX dropping pills</td>
<td>Flunarizine hydrochloride capsules</td>
<td>—</td>
<td>①</td>
<td>3 points</td>
</tr>
</tbody>
</table>

Abbreviation: “—”, This item is not involved in the study; C, medication in the control group; T, medication in the treatment group; YFNX, Yufeng Ningxin.

Notes: Western medicine routine 1: mainly includes antiplatelet aggregation, nitrates, β-blockers, etc., and nitroglycerin tablets are taken when angina pectoris occurs; Western medicine routine 2: low molecular weight heparin, statins, aspirin, isosorbide mononitrte; Western medicine routine 3: anticoagulation, nitrates, calcium channel blockers, lipid regulation, antiplatelet drugs, etc.; Western medicine routine 4: drugs of antiplatelet aggregation, stabilizing plaque, nourishing myocardium, etc.; Western medicine routine 5: aspirin, clopidogrel, low molecular weight heparin, statins, isosorbide mononitrte, etc., sublingual intake of nitroglycerin during angina attack; (1) clinical efficacy; (2) EKG curative effect; (3) the number of angina attacks; (4) duration of angina pectoris; (5) 6-minute walking test; (6) NO level; (7) CRP level; (8) homocysteine (Hcy) level; (9) the number of headache attacks; (10) duration of headache; (11) fibrinogen level; (12) hemorheology; (13) adverse reactions.
on the electrocardiogram (ECG) of coronary heart disease, and the dosage forms were YFNX dropping pills.5,10 The clinical judgment criteria of ECG efficacy included markedly effective, effective, and ineffective. The results of meta-analysis of the fixed-effect model showed that compared with the simple Western medicine group, YFNX dropping pills combined with the Western medicine group could significantly improve the ECG of coronary heart disease, and the difference was statistically significant (RR = 1.36, 95%CI [1.14, 1.62], p = 0.0006). See Fig. 5.

Analysis of the Number and Duration of Angina Pectoris Attacks in Coronary Heart Disease
Three studies observed the effect of YFNX preparations + Western medicine group versus Western medicine group on the frequency and duration of angina pectoris attacks in coronary heart disease.

Fig. 2 Meta-analysis forest plot of clinical efficacy of YFNX preparations + Western medicine group versus Western medicine group in the treatment of coronary heart disease.

YFNX, Yufeng Ningxin.

Fig. 3 Meta-analysis forest plot of clinical efficacy of YFNX preparations + Western medicine group versus Western medicine group in the treatment of hypertension.

YFNX, Yufeng Ningxin.

Fig. 4 Meta analysis forest plot of clinical efficacy of YFNX preparations + Western medicine/YFNX preparations VS Western medicine in the treatment of neuropathic headache.

ECG, electrocardiogram; YFNX, Yufeng Ningxin.

Fig. 5 Meta-analysis forest plot of ECG efficacy of YFNX preparations + Western medicine group versus Western medicine group in the treatment of coronary heart disease.

fig
The results showed that the data had a high degree of heterogeneity \((p < 0.00001, I^2 = 99\%)\), and the data consistency was still large after sensitivity analysis, so descriptive analysis was performed. The results showed that compared with the simple Western medicine group, YFNX preparations combined with the Western medicine group could significantly reduce the frequency and duration of angina pectoris attacks of coronary heart disease, and the difference was statistically significant. See ►Figs. 6 and 7.

### Analysis of Fibrinogen Levels

Two studies reported the effect of YFNX preparations + Western medicine group versus Western medicine group on the level of fibrinogen in coronary heart disease, both of which were in the form of YFNX dropping pills.\(^7,17\) The meta-analysis of the fixed-effect model showed that YFNX dropping pills combined with the Western medicine group could significantly reduce the level of fibrinogen compared with that treated by the simple Western medicine group, and the difference was statistically significant \((\text{MD} = -0.64, 95\% \text{CI} [-0.99, -0.3], p = 0.0003)\). See ►Fig. 8.

### Analysis of Headache Score, Number of Headache Attacks, and Duration of Neuropathic Headache

In two research articles, the effects of YFNX dropping pills combined with the Western medicine group on headache score, attack frequency, and duration of neuropathic headache were observed, and the dosage forms were all YFNX dropping pills.\(^5,12\) The analysis results showed that the data had high heterogeneity \((p < 0.00001, I^2 = 97\%\); \(p < 0.00001, I^2 = 97\%\); \(p < 0.0001, I^2 = 94\%)\); the data consistency was still large after sensitivity analysis, so descriptive analysis was performed. The results of headache score and headache duration showed that compared with the simple Western medicine group, the combination of YFNX dropping pills and the Western medicine group could significantly reduce the headache score and shorten the duration of headache, and the difference was statistically significant. The results of the number of headache attacks showed that compared with the simple Western medicine group, one study reported that YFNX dropping pills combined with the Western medicine group could significantly reduce the number of headache attacks, and the difference was statistically significant;\(^12\) while another study reported that the difference was not statistically significant. See ►Fig. 9–11.\(^9\)
Adverse Reactions
Three research articles reported the adverse reactions of YFNX dropping pills/tablets in the treatment of coronary heart disease, and one of them reported that there were no adverse reactions in the two groups.6,10,11 One research reported one case of headache in the control group, one case of constipation, one case of nausea, and one case of headache in the treatment group, and the incidence of adverse reactions between the two groups was not statistically significant. One research reported one case of abdominal distension, two cases of fatigue, and one case of constipation in the treatment group, and two cases of dizziness, three cases of headache, one case of abdominal distension, seven cases of fatigue, six cases of constipation, eight cases of dry mouth, and three cases of nausea in the control group. The incidence of adverse reactions was 5.00% and 36.25%, respectively.

Publication Bias
Because the number of included studies was small and most of them were different diseases, the combined analysis could not be performed and no funnel plot was drawn.

Discussion
Cardiovascular and cerebrovascular diseases are the general term of cardiovascular and cerebrovascular diseases, generally referring to ischemic or hemorrhagic diseases of the heart, brain, and systemic tissues caused by blood viscosity, hyperlipidemia, and atherosclerosis in Western medicine,33 which are equivalent to “chest pain and heart pain,” “stroke” “dizziness” and “headache” in TCM. In TCM, it believes that the fundamental pathogenesis of cardiovascular and cerebrovascular diseases lies in “blood stasis,” and blood stasis syndrome is a common syndrome of various cardiovascular and cerebrovascular diseases. Promoting blood circulation and removing blood stasis is a basic therapeutic method in TCM, which promotes a smooth flow of blood by dredging the blood vessels and removing blood stasis, thus having therapeutic and preventive effects on the cardiovascular and cerebrovascular diseases. Studies have shown that Chinese herbs with the effect of promoting blood circulation and removing blood stasis have the functions of dissolving blood stasis, promoting blood circulation, improving platelet activity, regulating blood lipids, resisting platelet aggregation, and reducing the occurrence of thrombosis. In the clinical treatment of cardiovascular and cerebrovascular diseases, these herbs are often used to increase blood flow velocity, reduce blood viscosity, red blood cell aggregation, blood congestion and capillary permeability, and improve vascular status and vascular oozing.34 Therefore, Chinese herbs with the effect of promoting blood circulation and removing blood stasis have high clinical value in the treatment of cardiovascular and cerebrovascular diseases.

The clinical dosage forms of YFNX preparations include dropping pills, tablets, capsules, and granules, and dropping pills are the main dosage forms currently used in clinical practice. The main component of YFNX dropping pills is puerarin, which has the functions of dilating blood vessels, relieving spasm and pain, and increasing blood flow of heart and cerebral blood and has a significant effect on the prevention and treatment of cardiovascular and cerebrovascular diseases. Studies have shown that the drug can be used for coronary heart disease, neuropathic headache, hypertension, vertebrobasilar insufficiency, transient cerebrovascular attack, chronic arrhythmia, cerebral vasospasm, sudden deafness, myocardial ischemia, etc. Meta-analysis results showed that compared with the simple Western medicine group, YFNX preparations + Western medicine group/YFNX preparation group can significantly improve the clinical efficacy of coronary heart disease, hypertension and neurological headache, improve the ECG of coronary heart disease, reduce the frequency and duration of angina pectoris of coronary heart disease, lower the fibrinogen level and headache score, shorten the duration of headache, and reduce the number of headache attacks, with statistically significant difference. In terms of adverse reactions, only three articles reported adverse reactions in the included studies. The reported adverse reactions included constipation, headache, dizziness, nausea, abdominal distension,
fatigue, etc. The number of adverse reactions was small, and the difference was not statistically significant. Limitations of this study: (1) the quality of the included studies is not high enough. Among the 13 included studies, 6 were clinical randomized controlled studies and 7 were case–control studies. Only one of the randomized controlled clinical trials was of high quality, one of the case-control studies was of moderate quality, and the rest of the articles were of low quality. (2) The included studies were all single-center studies, most of the experiments were small sample, and no study estimated the sample size, which may affect the reliability of the results. (3) The treatment course and dose of each study were different, and the clinical heterogeneity could not be completely eliminated.

To sum up, YFNX preparations are effective for cardiovascular and cerebrovascular diseases such as coronary heart disease, hypertension, neuropathic headache, and no serious adverse reactions have been found. Limited by the quantity and quality of the included studies, the above conclusions need to be verified by more high-quality studies.

Credit Authorship Contribution Statement

Lishuang Zhang: Data curation, visualization, software, formal analysis, and writing—original draft. Yaxia Ma: Data curation, formal analysis, and software. Ying Wang: Formal analysis, and writing—original draft. Feng Jiang: Conceptualization, methodology, funding acquisition, and writing—review & editing.

Funding

This work was supported by Tianjin Municipal Education Commission Scientific Research Program (2021KJ170).

Conflict of Interest

The authors declare no conflict of interest.

References

16. He CF. Forty-two cases with hypertension accompanied with headache treated with Yufeng Ningxin tablets. Heal 2014;8(10):152
23. Yang YL, Tang YQ, Jiang WD. Fifty cases with dizziness due to vertebrobasilar insufficiency treated by Yufeng Ningxin tablets combined with Yinxing Damo injection. Zhejiang J Tradit Chin Med 2010;45(09):700
29. Liu YD, Shi YH, Li JT. Fifty-eight cases with senile myocardial ischemia treated with Yufeng Ningxin tablets J. Zhong Yi Xue 2003;44(02):126